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Abstract
Background/Aims: Liver transplantation (LTx) is the only
established treatment in patients with end-stage primary
biliary cirrhosis (PBC). Although short-term survival after
LTx in this group of patients is usually good, few data
exist on the long-term survival. The optimal timing of
transplantation is difficult. Thus, the aims of this study
were to assess the long-term survival of patients with
PBC after LTx and to identify potential predictive factors
for a positive outcome. Methods: Survival of 28 patients
with PBC who underwent LTx between 1985 and July
1999 in a single center was studied by Kaplan-Meier
analysis and was compared to predicted survival without
LTx using established prognostic models for PBC, the
Mayo and European risk scores. Potential prognostic
parameters obtained before LTx were tested for correla-
tion to survival. Rates of bone fractures as markers of
hepatic osteodystrophy were compared before and after
LTx. Results: Median follow-up after LTx was 90 months
with a maximum of 140 months. Actuarial survival of
patients with PBC was 89% after 1, 5, and 10 years and
was significantly better than estimated survival without
LTx after 1–7 years as calculated by the Mayo and Euro-
pean risk scores. Of several parameters tested, only
serum bilirubin and the prognostic scores, but no other
liver function tests obtained immediately prior to trans-
plantation were significantly correlated with survival af-
ter LTx. The duration of intensive care after LTx was not
associated with any parameters obtained before LTx.
Bone fractures were diagnosed in 43% of patients of
whom the vast majority were osteopenic before LTx as
determined by osteodensitometry. Conclusion: Long-
term survival of a well-defined group of patients with
PBC was excellent after LTx and was inversely correlated
with preoperative serum bilirubin levels as well as Mayo
and European risk scores.
Copyright © 2000 S. Karger AG, Basel
Introduction
Primary biliary cirrhosis (PBC) is the most frequent
chronic cholestatic liver disease in adults with a preva-
lence between 2 and 24 per 100,000 [1]. Though immune
mechanisms have been associated with the characteristic
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histological finding of nonsuppurative destructive cholan-
gitis [2], the pathogenesis of PBC still remains unclear and
treatment is difficult. Numerous drugs have been evaluat-
ed for the treatment of PBC, but to date only ursodeoxy-
cholic acid has been proven to be a safe and effective drug
that may slow the progression of this disease [3]. In the
end stage of PBC, liver transplantation (LTx) has been
proven to be highly effective [4]. Thus, the identification
of risk factors and an estimation of survival with or with-
out LTx for these patients is needed to achieve an ade-
quate timing of LTx [4–7]. Several prognostic indices
have been established to predict the probability of surviv-
al in patients with PBC, of which the Mayo risk score [6]
and the updated European risk score [7] are most widely
used. Additional prognostic scores have been introduced
to predict the amount of intraoperative blood loss, num-
ber of days in the intensive care unit (ICU), and severe
complications after surgery [8]. However, optimal timing
for LTx in the individual patient with PBC still remains
difficult. In addition, the waiting time for LTx is increas-
ing due to the lack of donor organs, and this leads to an
increased mortality on the waiting list [9].
The aim of this study was to compare the long-term
survival of patients with PBC after LTx to estimated sur-
vival without LTx using the Mayo as well as the European
prognostic model. In addition, baseline characteristics of
the patients were correlated with survival following LTx
and with the duration of intensive care. Since osteodystro-
phy is a major complication of advanced PBC and may
aggravate after LTx due to corticosteroid treatment and
transient immobilization, rates of bone fractures and
bone density were compared before and after LTx.
Patients and Methods
Between 1985, when the LTx program started at the University of
Munich, and the final follow-up on July 1, 1999, 28 patients (27
women, 1 man) with PBC underwent LTx, representing 9% of all
indications for LTx in the program. All patients received AB0 com-
patible grafts. Cardiovascular diseases, malignancies, infections and
concomitant liver diseases were excluded before patients were listed
for LTx. Long-term immunosuppression was maintained with cy-
closporin or tacrolimus according to blood levels and 5 mg predniso-
lone equivalent daily. Patient data from the last follow-up visit before
LTx (range 2 days to 2 months before LTx) were used for the calcula-
tion of risk scores. After LTx, patients were followed on a yearly basis
as outpatients by physicians of the transplant program and were
readmitted to the inpatient service for all LTx-related complications
during follow-up. No patient was lost to follow-up.
The median age of the 27 women and 1 man with PBC at trans-
plantation was 54 (36–65). Median follow-up after LTx was 90
months with a maximum of 140 months. At transplantation, 45% of
Table 1. Baseline characteristics of patients with PBC before LTx
(n = 28)
Characteristic Median Range
54 36–65
Bilirubin, mg/dl 14.9 2.5–49.2
Albumin, g/dl 3.4 2.5–4.2
Creatinine, mg/dl 0.9 0.6–1.7
Prothrombin time, % 65 42–100
ABT, % 0.134 0.018–0.608
Time in the ICU, days 15 1–75
Mayo model 8.224 6.367–11.016
European model 2.581 0.321–5.375
Child-Pugh score1 A (5–6 points) 0%
B (7–9 points) 68%
C (610 points) 32%
UNOS status 1 (ICU/liver failure) 0%
2 (hospitalized) 45%
3 (continuous care) 55%
Biochemical results were obtained within 2 months prior to
LTx.
UNOS = United Network for Organ Sharing.
1 Child-Pugh score was modified for PBC as proposed by Pugh et
al. [10].
patients were hospitalized and 55% received continuous medical
care, but were at home. The median serum bilirubin level was 14.9
(2.5–49.2) mg/dl. Renal function as assessed by serum creatinine lev-
els was normal in 26 and only mildly impaired in 2 of 28 patients.
The median creatinine level was 0.9 (0.63–1.7) mg/dl. All character-
istics of the patient population are summarized in table 1.
Osteodensitometry was performed in the lumbar spine using CT
until July 1991 when QDR was introduced. After July 1991, QDR of
the lumbar spine became the method of choice for osteodensitometry
due to low radiation exposure and high diagnostic accuracy.
Prognostic Models for Survival
The actual survival time after LTx was compared to the esti-
mated survival time without LTx as calculated by two prognostic
scores for patients with PBC, the Mayo risk score and the European
risk score [6, 7]. These models were chosen, because they are cross-
validated and do not require inclusion of histological parameters for
estimation of prognosis. Both models are based on Cox’s proportion-
al hazards model and can be used to calculate a prognostic index for
any patient at a given time.
The Mayo model described by Dickson et al. [6] includes five
variables which independently predict survival in PBC. The prognos-
tic index R is calculated from these variables using the following
equation: R = 0.871 ! loge (bilirubin [mg/dl]) – 2.53 ! loge (albumin
[g/dl]) + 0.039 ! age (years) + 2.38 ! loge (prothrombin time [s]) +
0.859 ! edema (0 = no edema, no diuretic therapy; 0.5 = edema, no
diuretic therapy or no edema, diuretic therapy; 1 = edema and diuret-
ic therapy).
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Fig. 1. Actuarial and estimated survival of
patients with PBC. Actuarial survival of pa-
tients with PBC after LTx (Kaplan-Meier)
was significantly better (p ! 0.01–0.001)
than the estimated survival without LTx as
calculated by the Mayo and European prog-
nostic models for time points of 1–7 years
after LTx. The number of patients followed
is given in parentheses for all time points.
The European model described by Christensen et al. [7] includes
six independent prognostic variables. These variables are used to cal-
culate the prognostic index PIAI as follows: PIAI = 2.53 ! (log biliru-
bin [Ìmol/l] – 1.53) + 1.39 ! ascites (0 = no; 1 = yes) – 0.089 !
(albumin [g/l] – 34.3) + 0.04 ! (age [years] – 55) + 0.65 ! GI bleed-
ing (0 = no; 1 = yes).
Prognostic Model for Duration of ICU Stay
Recently, a prognostic score has been proposed to predict the
number of days in the ICU after LTx for patients with cholestatic
liver disease [8]. ICU score = –48 + (1.1 ! age [years]) + (63 ! renal
failure [0 = no; 1 = yes]) + (25 ! Child’s class [A = 1; B = 2; C = 3]) –
(19 ! UNOS status [1 = ICU/liver failure; 2 = hospitalized; 3 = con-
tinuous care; 4 = at home]). In this model, renal failure is defined as
serum creatinine 12.0 mg/dl and/or urine output !10 ml/kg/24 h. A
modified Child’s classification for patients with cholestatic liver dis-
ease was used to calculate the Child-Pugh score [8]. 
Statistical Methods
Survival time was defined as the interval between the first LTx
and death or final follow-up (July 1, 1999). Retransplantation per-
formed in 3 patients due to graft failure was disregarded because
patient survival, not graft survival was analyzed. Thus, each of these
patients was included in the study only once and the time point of the
initial transplantation was used for the follow-up. Survival was calcu-
lated using the Kaplan-Meier analysis. Estimated survival time for
patients without LTx was calculated as described above [6, 7]. The
difference between estimated and actuarial survival was analyzed by
using the ¯2 test. Correlation of baseline characteristics to survival
and duration of time on an ICU was tested by using Wilcoxon’s test
for unpaired samples. A p ! 0.05 was considered statistically signifi-
cant.
Results
Survival
Of 28 patients who underwent LTx for PBC, 25 (89%)
were alive at the endpoint of follow-up; median follow-up
was 90 months with a maximum of 140 months. All lethal
outcomes were related to early mortality: 3 patients died
within 1 week of transplantation, 1 due to primary graft
dysfunction, and two due to bleeding complications.
These 3 patients also had advanced disease as indicated
by a Child-Pugh score of 11, 11, and 10 points, respective-
ly. The actuarial survival rate after LTx was 89% from
year 1 to 7 using the Kaplan-Meier estimate, and higher
than the estimated survival rate using the Mayo as well as
the European prognostic model (fig. 1). These differences
between the actuarial survival and the estimated survival
without LTx were highly significant for all time points
(year 1–7) and both models used.
Several parameters of potential prognostic value were
tested for a possible association with the outcome of LTx
in our patient population. Of these parameters, preopera-
tive serum bilirubin levels (p ! 0.001) as well as the Euro-
pean and Mayo prognostic scores (p ! 0.05, each) were
significantly correlated with survival after LTx (fig. 2). In
contrast, age, albumin, prothrombin time and hepatic
microsomal demethylation capacity as determined by the
aminopyrine breath test (ABT; fig. 2) were not significant-
ly associated with survival.
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Fig. 2. Prognostic factors for survival after
LTx. Serum bilirubin, Mayo and European
risk scores, and aminopyrine breath test
(ABT) of patients with PBC obtained within
2 months prior to LTx. [ = Values of pa-
tients surviving LTx; P = patients who died
after LTx. Differences between values of sur-
viving and nonsurviving patients were statis-
tically significant for serum bilirubin (p !
0.001), Mayo (p ! 0.01) and European risk
score (p ! 0.01), but not for the ABT.
Duration of Intensive Care
After LTx, patients were treated for a median of 15
(1–75) days in an ICU. The 3 patients who died after
transplantation were disregarded for these calculations.
No correlation was found between potential prognostic
variables determined before LTx (bilirubin, prothrombin
time, age, albumin, ABT, Mayo and European score) and
the duration of intensive care. In addition, a prognostic
score proposed by Ricci et al. [8] to estimate the number
of days on an ICU after LTx did not predict the period of
intensive care in our patient population when the actual
days on the ICU were compared to the putative number
of days as calculated by this model. However, the median
stay in an ICU was only 3 days in the study population of
Ricci et al. [8], whereas we observed a median stay of 15
days.
Osteodystrophy
Bone fractures are the major manifestation of hepatic
osteodystrophy in patients with PBC and may lead to dis-
ability before as well as after LTx. In our unit, patients
were receiving calcium supplementation (1,000 mg daily)
before and after LTx. In addition, patients were also sup-
plemented with vitamin D3 (cholecalciferol 0.025–0.050
mg equivalent to 1,000–2,000 IU vitamin D3 daily), when
their serum level of 25-hydroxycholecalciferol was in the
low normal range or below the normal range. Bone frac-
tures mainly of lumbar and thoracic vertebrae were diag-
nosed in 32% of patients before LTx. All these patients
had a bone density (as determined in the lumbar spine) of
more than 1 SD below that of healthy women of the same
age. Another 25% of patients who presented with bone
densities lower than 1 SD below that of healthy controls
did not develop fractures before LTx. However, one or
more new fractures were observed in 28% of patients sur-
viving LTx (first fracture in 11%). Again, fractures mainly
affected the vertebrae and all but 1 patient had a bone
density of more than 1 SD below the bone density of
healthy controls. Taken together, osteodystrophy was a
common complication and led to bone fractures in 43% of
patients under study before and/or after transplantation.
Discussion
This study shows that the beneficial effect of LTx on
survival of patients with PBC is maintained for a median
follow-up of 90 months and a maximum survival of more
than 11 years, the longest follow-up reported so far. LTx
significantly improved the long-term survival of patients
with PBC when compared to predicted survival without
transplantation. The cumulative survival of 89% ob-
served up to 11 years after LTx appears remarkable and is
comparable or superior to the 5-year patient survival
reported previously [11–15].
Survival of patients with PBC has been less favorable
in previous decades although patient characteristics were
comparable. In addition, follow-up time is shorter in most
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papers. Markus et al. [12] followed 161 patientswith PBC
after LTx between 1980 and 1987. Baseline characteristics
were similar to our patients with regard to serum bilirubin,
prothrombin time and Mayo risk score, but with a median
of 47.8 years these patients were on average 7 years youn-
ger at transplantation. The median follow-up was 25
months and the actuarial survival 1 year after LTx was
76%. Keiding et al. [11] followed 137 patients, who
received LTx for PBC in Nordic countries between 1982
and 1988 for a median of 13 months. Actuarial survival
after 1 year was 75% in their study population. Bonsel et al.
[13] followed 30 patients with PBC after LTx between
1978 and 1989. The patients of their study were younger
(median 49.6 years), serum bilirubin was lower (median
11.7 g/dl) and median follow-up was 30 months with a
maximum of 9.9 years. Despite the favorable baseline
characteristics, cumulative survival was only 65% after
1 year and about 60% after 5 years. These differences in
survival time when compared to our study might be
explained by advances in perioperative and posttransplan-
tation patient management during the last 10–20 years.
More recently, Knoop et al. [14] reported a 5-year sur-
vival rate of 95% in 49 patients with PBC. The median
preoperative serum bilirubin was 8.9 g/dl as compared to
14.9 g/dl in our study, suggesting less advanced disease
stages in their group of patients.
A Mayo risk score of 7.8 and higher has been associated
with a progressively increased mortality after LTx [15].
However, 71% of our patients had a Mayo risk score great-
er than 7.8. Thus, LTx may be successful with Mayo risk
scores of considerably more than 7.8, and additional
parameters and risk scores should be included and evaluat-
ed for the optimal timing of LTx in patients with PBC.
Serum bilirubin has been shown to be a potent predictor of
survival in untreated patients with PBC [16–18]. In our
study, pretransplant serum bilirubin levels were signifi-
cantly associated with survival after LTx confirming a pre-
vious report [15]. Indeed, patients with pretransplant
serum bilirubin levels above 27 g/dl did not survive the
first week after LTx. Prospective evaluation of the prog-
nostic value of serum bilirubin for the outcome of LTx in
PBC is clearly of interest. The European and Mayo prog-
nostic models, each including serum bilirubin, were also
correlated to survival. Age has been inversely related to
survival in untreated patients with PBC [5–7], but was not
correlated to survival after LTx in our study. The hepatic
demethylation capacity as determined by the ABT was not
associated with survival after LTx in the patients studied.
However, the ABT is of limited value in the assessment of
disease severity in patients with cholestasis [19]. The lim-
ited number of patients in our study may have precluded
the identification of additional factors potentially predic-
tive for the outcome of LTx in PBC.
The duration of intensive care was not correlated to
any of the potential prognostic factors studied in our
patients. In addition, a prognostic model proposed to pre-
dict the duration of intensive care after LTx in patients
with cholestatic liver disease could not be applied to our
patients. However, Ricci et al. [8] reported a median peri-
od on ICU of 3 days compared to a median of 15 days in
our study. Thus, the model of Ricci et al. [8] might not be
applicable to the conditions met in most transplantation
centers in Germany where patients are generally observed
for a longer time period on an ICU after LTx.
Osteoporosis and atraumatic fractures are serious
complications of PBC and may considerably worsen a
patient’s general condition after LTx [20]. Female pa-
tients with PBC have a reduced mean bone density when
compared to healthy women [21], resulting in atraumatic
fractures before and shortly after transplantation. In our
study, 57% of all patients had a decreased bone density
and more than half of these patients, equaling 32% of the
whole study population, developed one or more fractures
prior to transplantation. These numbers highlight the fact
that osteodystrophy is common in PBC patients and frac-
tures are a major complication before LTx. Bone density
should, therefore, be determined in all patients and pre-
ventive treatment started early in the course of disease.
After LTx, 28% of the surviving patients were diagnosed
with new bone fractures. All but one of these patients
again had decreased bone density, even though it has been
shown that bone mass may be restored towards normal
within 2–3 years after LTx [21]. However, all but 1 of our
patients were treated with low-dose corticosteroids after
LTx. This patient had severe osteodystrophy before trans-
plantation with fractures of several lumbar and thoracic
vertebrae. A long-term immunosuppression without cor-
ticosteroids was chosen for this patient to prevent pred-
nisolone-induced aggravation of bone loss after LTx.
Thus, treatment of osteodystrophy appears necessary be-
fore and after LTx in the majority of patients with PBC.
Recently, cyclical etidronate has been used successfully to
prevent bone loss in corticosteroid-treated PBC patients.
Bisphosphonates might provide a new treatment strategy
for this group of patients [22].
In summary, LTx proved to be beneficial in a group of
patients with PBC followed for a period of more than 10
years. Serum levels of bilirubin and multiparametric
prognostic indices were correlated to the outcome of LTx
in our patient group.
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